Life joins Abbott to develop companion diagnostic for GSK's Phase III cancer immunotherapy
This article was originally published in Clinica
Executive Summary
GlaxoSmithKline has signed up a second partner, Life Technologies, to develop a companion diagnostic which will identify patients who are more likely to benefit from a cancer immunotherapy currently being trialled by the pharma heavyweight.